Efficacy of treatment with lamivudine in patients with chronic active e- minus variant hepatitis B virus infection: A nonrandomized, open-label study

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 6, 2000, Pages 321-330

  Scotto, Gaetano ^a,d   Fazio, Vincenzina ^a   Campanozzi, Fausto ^b   D'Adduzio, Antonio ^c  

^a Ospedali Riunit   (Italy)

^b SERT FG/1   (Italy)

^c SERT FG/3   (Italy)

^d NONE   (Italy)

Author keywords

Antiviral therapy; Chronic active e minus variant HBV infection; Lamivudine

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SYNTHESIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; LIVER CLEARANCE; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0033921765     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80001-6     Document Type: Article

References (27)

1. 1. Maynard JE. Hepatitis B: Global importance and need for control. Vaccine. 1990;8 (Suppl):S18-S20.
2. 2. Liaw YF, Tai DI, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology. 1988;8:493-496.
3. 3. Dusheiko GM. Treatment and prevention of chronic viral hepatitis. Pharmacol Ther. 1995;65:47-73.
4. 4. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis. Ann Intern Med. 1993;119:312-323.
5. 5. Niaderau C, Heintges T, Lange S, et al. Long-term follow-up of HbeAg-positive patients treated with interferon-alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422-1427.
6. 6. Adzyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Viral Hep Rev. 1995;1:7-36.
7. 7. Naoumov NV, Schneider R, Groetzinger T, et al. Precore mutants hepatitis B virus infection and liver disease. Gastroenterology. 1992;102:538-543.
8. 8. Santantonio T, Jung MC, Miska S, et al. Prevalence and type of pre-C HBV mutants in anti-Hbe positive carriers with chronic liver disease in a highly endemic area. Virology. 1991;183:840-844.
9. 9. Hadziyannis S, Bramon T, Makris A, et al. Interferon alfa-2b treatment of HbeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol. 1990;11:S133-S136.
10. 10. De Man RA, Schalm SW, Main J, et al. A dose ranging study to determine the antiviral activity and safety of lamivudine (2-deoxy-3-thiacytidine) in patients with chronic hepatitis B infection. Gut. 1993;349:55. Abstract.
11. 11. Tyrrell DL, Mitchell MC, De Man RA. Phase II trial of lamivudine for chronic hepatitis B. Hepatology. 1993;18(Suppl):112A. Abstract.
12. 12. Dienstag JL, Perrilli RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-1661.
13. 13. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: A six-month randomised dose-ranging study. Gastroenterology. 1997;113:1258-1263.
14. 14. Lai CL, Ching CK, Tung AKM, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology. 1997;25:241-244.
15. 15. Lai CL, Chien RN, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61-68.
16. 16. Kruining J, Heijtink RA, Schalm SW. Antiviral agents in hepatitis B virus transfected cell lines: Inhibitory and cytotoxic effect related to time of treatment. J Hepatol. 1995; 22:263-267.
17. 17. Ashman C, Larkin D, Cannack N, et al. Lamivudine inhibits hepatitis B virus (HBV) production in the HBV transfected cell line 2.2.15. Sixth International Symposium on Viral Hepatitis; February 3 to 5, 1994; Madrid, Spain. Abstract.
18. 18. Tassopoulos NC, Volpes R, Pastore G, et al. Lamivudine therapy in patients with anti-HBe positive chronic hepatitis B: End of treatment analysis. J Hepatol. 1998; Suppl 1, 28:43, A: GS2/08.
19. 19. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow-up of patients with HbeAg negative chronic hepatitis B. J Hepatol. 1999;Suppl 1, 30:117, A:P/C06/015.
20. 20. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with HbeAg negative/HBVDNA positive (pre-core mutant) chronic hepatitis B. Hepatology. 1999;29:939-945.
21. 21. Honkoop P, De Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver. 1997;17: 103-106.
22. 22. Suzuki Y, Kumada H, Hikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol. 1999;30:743-748.
23. 23. Honkoop P, Niesters HGM, De Man RA, et al. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol. 1997;26:1393-1395.
24. 24. Honkoop P, De Man RA, Niesters HGM, Schalm SW. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol. 1998;29:510-511.
25. 25. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 1998;27:1711-1716.
26. 26. Zeuzem S, De Man RA, Honkoop P, et al. Dynamics of hepatitis B virus infections in vivo. J Hepatol. 1997;27:431-436.
27. 27. Nowak MA, Bonhoeffer S, Hill AM, et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 1996;93:4398-4402.